新浪登录
腾讯登录Affymetrix： 第四季度营收增加10%
| 导读 | Affymetrix reported after the close of the market Wednesday that its fourth quarter revenues climbed around 10 percent year over year, as sales growth for its consumables products and eBioscience busi... |
Affymetrix reported after the close of the market Wednesday that its fourth quarter revenues climbed around 10 percent year over year, as sales growth for its consumables products and eBioscience business more than offset a decline in instrument revenue.The microarray technologies firm brought in total revenues of $92.6 million for the three months ended Dec. 31, up from $84.3 million for Q4 2012. The revenues were slightly higher than the firm's preliminary announcement of an expected $91 million in revenues and above the consensus Wall Street estimate of $90 million.
Affy said that its product sales were $82.1 million versus $76.4 million for Q4 2012, and its services and other revenues were $10.5 million compared to $8 million.
Its product revenue for Q4 2013 included core consumable revenue of $57.6 million, instrument revenue of $4 million, and revenue from eBioscience of $20.5 million. That compares to Q4 2012 core consumable revenue of $53.1 million, instrument revenue of $5.2 million, and revenue from eBioscience of $18.1 million.
In its preliminary announcement of revenues a month ago, Affy said that the fourth quarter of 2013 included a one-time licensing payment of $5.3 million from an unnamed diagnostic partner.
Affy posted a profit of $9.4 million, or $.10 per share, for Q4 2013, compared to a profit of $12.3 million, or $.17 per share, for Q4 2012. On a non-GAAP basis, it had EPS of $.02, flat with the prior year and below analysts' consensus estimate of $.07.
The firm spent $12 million on R&D during the quarter, down 17 percent from $14.5 million. Its SG&A expenses increased nearly 3 percent to $39.1 million from $38.1 million.
For full-year 2013 Affy reported revenues of $330.4 million, up 12 percent from $295.6 million in FY 2012. The company beat the average analyst estimate of $327.9 million.
Its product sales for the year were $302.6 million compared to $266.1 million for 2012, and its services and other revenues decreased to $27.8 million from $29.6 million year over year. It said that eBioscience provided $78.2 million of its total revenues in 2013 versus $37 million in 2012.
Affy's net income for the year was $16.3 million, or $.23 per share, compared to $10.7 million, or $.15 per share, for FY 2012. On a non-GAAP basis, its EPS for the year was $.10, flat with 2012 and below the Street estimate of $.15.
"We made substantial progress on our strategic plan in 2013," Frank Witney, president and CEO of Affymetrix, said in a statement. "Our efforts in establishing ourselves in the translational medicine, molecular diagnostic, and applied science markets are clearly paying off. Last month we received 510(k) clearance from the US Food and Drug Administration for our CytoScan Dx test. In addition, we have introduced a number of new products that will further our position into large, rapidly growing markets such as tumor profiling and AgBio testing."
Affy finished the year with $57.1 million in cash and cash equivalents.
CFO Gavin Wood noted that the firm paid down more than $24 million against its senior debt during Q4, reducing its outstanding senior debt to around $39 million.
来源：
http://www.genomeweb.com/arrays/ ... ues-rise-10-percent
Affy said that its product sales were $82.1 million versus $76.4 million for Q4 2012, and its services and other revenues were $10.5 million compared to $8 million.
Its product revenue for Q4 2013 included core consumable revenue of $57.6 million, instrument revenue of $4 million, and revenue from eBioscience of $20.5 million. That compares to Q4 2012 core consumable revenue of $53.1 million, instrument revenue of $5.2 million, and revenue from eBioscience of $18.1 million.
In its preliminary announcement of revenues a month ago, Affy said that the fourth quarter of 2013 included a one-time licensing payment of $5.3 million from an unnamed diagnostic partner.
Affy posted a profit of $9.4 million, or $.10 per share, for Q4 2013, compared to a profit of $12.3 million, or $.17 per share, for Q4 2012. On a non-GAAP basis, it had EPS of $.02, flat with the prior year and below analysts' consensus estimate of $.07.
The firm spent $12 million on R&D during the quarter, down 17 percent from $14.5 million. Its SG&A expenses increased nearly 3 percent to $39.1 million from $38.1 million.
For full-year 2013 Affy reported revenues of $330.4 million, up 12 percent from $295.6 million in FY 2012. The company beat the average analyst estimate of $327.9 million.
Its product sales for the year were $302.6 million compared to $266.1 million for 2012, and its services and other revenues decreased to $27.8 million from $29.6 million year over year. It said that eBioscience provided $78.2 million of its total revenues in 2013 versus $37 million in 2012.
Affy's net income for the year was $16.3 million, or $.23 per share, compared to $10.7 million, or $.15 per share, for FY 2012. On a non-GAAP basis, its EPS for the year was $.10, flat with 2012 and below the Street estimate of $.15.
"We made substantial progress on our strategic plan in 2013," Frank Witney, president and CEO of Affymetrix, said in a statement. "Our efforts in establishing ourselves in the translational medicine, molecular diagnostic, and applied science markets are clearly paying off. Last month we received 510(k) clearance from the US Food and Drug Administration for our CytoScan Dx test. In addition, we have introduced a number of new products that will further our position into large, rapidly growing markets such as tumor profiling and AgBio testing."
Affy finished the year with $57.1 million in cash and cash equivalents.
CFO Gavin Wood noted that the firm paid down more than $24 million against its senior debt during Q4, reducing its outstanding senior debt to around $39 million.
来源：
http://www.genomeweb.com/arrays/ ... ues-rise-10-percent
还没有人评论，赶快抢个沙发